Loading clinical trials...
Loading clinical trials...
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Conditions
Interventions
SL-801
Locations
6
United States
Yale Cancer Center
New Haven, Connecticut, United States
Florida Cancer Specialist
Sarasota, Florida, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Mary Crowely Cancer Research Centers- Medical City
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Washington, Seattle Cancer Care Alliance
Seattle, Washington, United States
Start Date
February 23, 2016
Primary Completion Date
October 6, 2021
Completion Date
October 13, 2021
Last Updated
February 10, 2025
NCT07489378
NCT07181681
NCT07204340
NCT07360314
NCT07403721
NCT07395258
Lead Sponsor
Stemline Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions